Quest Diagnostics Incorporated

- The transcript does not mention any current or planned fundraising through debt or equity. - 2026 guidance includes expectations for cash from operations (~$1.75 billion), capital expenditures (~$550 million), and consistent share count and interest expense compared to 2025. - There is no indication of new debt issuance or equity offerings within the provided pages. - The company states that 2026 revenue guidance does not include any contribution from prospective M&A, suggesting a cautious approach to growth but no explicit fundraising plans. - Overall, no explicit plans for new fundraising via debt or equity are disclosed in the discussed call.

- $550 million capital expenditures forecasted for 2026, consistent with 2025 levels (Page 3). - Significant portion of capital investments allocated to esoteric labs for capacity upgrades to support advanced diagnostics growth (Page 11). - Continued investments in advanced diagnostics, including brain health biomarkers (AB 42/40, ApoE, NFL, p-tau181/217), cardiometabolic testing, and oncology partnerships (Page 11). - Ongoing support for Haystack cancer detection test, including commercial ramp and reimbursement efforts (Page 11-12). - Scaling planning and design for Project Nova, a multi-year initiative to transform order-to-cash processes with first wave implementation expected in fall 2027 (Page 3, 6). - No specific M&A contribution included in 2026 guidance, but M&A funnel remains active with ongoing evaluations of health system outreach deals (Page 12).

- Q1 2026 organic volume growth was strong at 10.8%, with total volume growth at 10.9%. - Excluding Corewell and Fresenius partnerships, organic volume growth was 3.8%. - Fresenius and Corewell collaborations contribute approximately 7% to organic volume growth. - Revenue guidance for 2026 raised to $11.78B to $11.9B, reflecting 6.8% to 7.8% growth. - Continued strong growth expected in physician, hospital, and consumer health channels. - Advanced diagnostics and consumer health segments show strong double-digit growth. - Partnerships and collaborations, including with wellness and wearable companies, expected to further accelerate growth. - Higher test per requisition driven by advanced tests and screening options supports revenue per requisition growth. - Corewell and Fresenius expected to add approximately $330-$350 million combined revenue growth in 2026. - Seasonality: Just over 49% of revenue and EPS in the first half, slightly over 50% in the second half, with continued strong organic utilization.

- Full year 2026 revenue guidance raised to $11.78 billion - $11.9 billion, a growth rate of 6.8% to 7.8%. - Reported EPS guidance updated to $9.58 - $9.78. - Adjusted EPS guidance raised to $10.63 - $10.83, reflecting strong first quarter momentum. - Operating margin expected to expand versus prior year. - Productivity gains from automation and AI to support earnings growth. - Project Nova investments expected to cause $0.25 EPS dilution for 2026, with expenses ramping more in second half. - Margin profile improvements anticipated, especially from partnerships (e.g., Fresenius) as businesses ramp. - EPS improvement expected over course of the year but early to quantify dilution or improvement specifics. - No M&A contribution included in 2026 guidance; M&A pipeline remains active but cautious. - Fuel cost inflation embedded in guidance; estimated $0.05 to $0.07 EPS impact.

The provided document does not explicitly mention details about the current or expected order book or pending orders. However, insights related to demand and growth can be inferred: - Solid first quarter results indicate strong demand for diagnostic solutions. - Organic volume growth was 10.8% in Q1 2026, showing broad-based utilization increases. - Growth driven by Corewell Health and Fresenius Medical Care collaborations contributing around 7% to volume growth. - Consumer health and wellness partnerships, including wearables and AI-driven testing, are expanding. - Increased longitudinal testing and test-per-patient trends due to AI, wearables, and consumer-initiated testing are expected. - Ongoing M&A activities with a healthy funnel of potential deals, though no contributions forecasted in 2026 guidance. - Project Nova and AI initiatives suggest future operational efficiency improvements, potentially supporting order processing. No specific figures for order backlog or pending orders are disclosed in the document.